PITTSBURGH, Aug. 5 /PRNewswire/ -- CardiacAssist, Inc. announced that it reached a new seasonal high of over 50 cases performed in the month of July, despite the recent FDA 510(k) approval and follow on industry attention to the Abiomed Impella 2.5 device. The TandemHeart's higher flow rate, minimal complications and versatility in deployment to critically ill patients without traumatic surgery will continue to increase the device's presence in heart centers in this country and abroad. When considering valve procedures and right heart cases that cannot be supported by the Impella 2.5, the TandemHeart is the only percutaneous solution. More than 125 hospitals worldwide now use the TandemHeart System in the Cath Lab and/or Operating Room for extracorporeal circulatory support.
Four new centers have also added the TandemHeart System to their Cath Lab or OR. The four new TandemHeart Centers of Excellence are:
"We're pleased to have such prestigious cardiac care facilities join our Centers of Excellence that are now using the TandemHeart," said Michael Garippa, President and CEO of CardiacAssist, Inc. "The adoption rate for this technology continues to increase, and our commercial experience with the TandemHeart will soon reach 1,500 cases.
The TandemHeart is fully reimbursed by Medicare under existing DRG codes. The device can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support. To date, the TandemHeart has been used in 28 countries by 125 different facilities by 200 different physicians.
CONTACT: Monica Bush, Marketing Specialist of CardiacAssist, Inc.,
+1-412-963-7770 ext. 247, or mbush@cardiacassist.com
Web site: http://www.cardiacassist.com/
